Table 2.
Frequency distributions of investigated markers among different studied groups
| Groups | Markers | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| VEGF (fold change) | Cyclin D1 (fold change)a | miR-373 (fold change)a | |||||||
| Mean ranka | ≤ 38b | > 38 | Mean ranka | ≤ 38 | > 38 | Mean ranka | ≤ 360 | > 360 | |
| Healthy individuals | 32.86 | 49 (100%) | 0 (0%) | 30.92 | 49 (100%) | 0 (0%) | 27.04 | 49 (100%) | 0 (0%) |
| Benign lesions | 88.78 | 73 (96.1%) | 3 (3.9%) | 91.59 | 72 (94.7%) | 4 (5.3%) | 92.57 | 75 (98.7%) | 1 (1.3%) |
| Primary breast cancer | 221.05 | 14 (7.1%) | 182 (92.9%) | 220.43 | 16 (8.2%) | 180 (91.8%) | 221.03 | 17 (8.7%) | 179 (91.3%) |
aAnalysis using non-parametric mean rank test by Kruskal-Wallis test (as to calculate the average of the ranks for the marker among the enrolled groups)
bChi-square test with statistical significance at P< 0.0001